Dose-dense effect: other contributors – Author's reply : The Lancet Oncology

abstract

"Kesikli and colleagues argued that results shown by the JGOG 3016 study for dense-dense paclitaxel in ovarian cancer 1 were caused by a higher cumulative dose received by the dose-dense group and by antiangiogensis effects of paclitaxel rather than by the dose-dense administration of the drug. However, increased dose of paclitaxel in ovarian cancer has shown no survival benefit in previous studies. Bolis and colleagues 2 compared standard-dose paclitaxel 175 mg/m 2 plus carboplatin with increased dose ... (to read further requires $$$)